DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
Cooperation Between CLIA-Certified Cancer Diagnostics Laboratory and Canadian Tech-Bio Company Will Allow Artificial Intelligence Models to Interrogate World's Largest Primary Tumor BiobankDiaGen gains access to 70,000+ primary tumor biobank, including world's largest gynecologic cancer biopsy repository, for therapeutic target discovery/validationFifteen anticancer peptides (ACPs) being leveraged for target identification and comparator for AI-enabled in silico small molecule candidate library creationIn vitro proof-of-concept for DiaGen's ACPs established in breast cancer cell lines, including triple negative breast cancer, with potential applications in additional tumor types to be evaluated under the partnership based on the pioneering research co-authored by DiaGen Chief AI Officer Mohit Pandey, Ph.D., published in Nature CommunicationsHelomics biobank allows for primary tumor therapeutic candidate screening and target engagement confirmation in GI cancer, brain cancer, breast cancer, head and neck cancer, genitourinary cancer, liver cancer, lung cancer, melanoma, mesothelioma, ovarian cancer, pancreatic cancer, sarcomas and uterine cancer